Norio Nakatsuji/X
Jun 20, 2026, 07:09
Norio Nakatsuji: LRP5 Inhibition Shows Promise for Safer Blood-Thinning Strategies
Norio Nakatsuji, Professor Emeritus at Kyoto University, Director General at Nakatsuji Foresight Foundation, Chief Advisor at Stem Cell and Device Lab, Inc. Bluesky, shared on X:
”LRP5 Inhibition Shows Promise for Safer Blood-Thinning Strategies
‘LRP5 inhibition reduced platelet activation and thrombosis with lower bleeding impact than current drugs.”’

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 14, 2026, 15:30Patient Selection for Gene Therapy in Transfusion-Dependent β-Thalassemia – EHA
-
Nov 14, 2026, 15:07Vaidehi Prasanth: Patient Blood Management in Hematological Patients A New Book Chapter
-
Nov 14, 2026, 15:00Ram Mohan Jaiswal: International Collaboration in Transfusion Medicine Through the Trans Med Africa Consortium
-
Nov 14, 2026, 14:48Jamie Sin Ying Ho: Stopping Anticoagulation After AF Ablation and Rhythm Control
-
Nov 14, 2026, 14:29Satya Prakash: Cell-Free Hemoglobin-Based Oxygen Carriers and Their Clinical Development
-
Nov 14, 2026, 14:24Adela Castro: Distinguishing Antiphospholipid Antibodies From APS in Pregnancy
-
Nov 14, 2026, 14:20Uzima Chirwa: Rethinking Comprehensive Care for Bleeding Disorders in Africa
-
Nov 14, 2026, 14:19Samuele Ferrari: Launching a New Era in Hematopoietic Genome Editing Research
-
Nov 14, 2026, 14:17Stefan Hofer: International Training in Postpartum Hemorrhage Management